Over the last 7 days, the United States market has experienced a 3.7% decline, although it has shown a 6.9% increase over the past year with earnings projected to grow by 14% annually. In this context of fluctuating yet promising growth, identifying high-growth tech stocks involves evaluating their potential for innovation and scalability in alignment with broader market trends.

Top 10 High Growth Tech Companies In The United States

Name Revenue Growth Earnings Growth Growth Rating TG Therapeutics 26.19% 37.78% ★★★★★★ Alkami Technology 21.98% 85.17% ★★★★★★ Travere Therapeutics 28.43% 65.01% ★★★★★★ AVITA Medical 27.78% 55.33% ★★★★★★ Clene 61.16% 59.11% ★★★★★★ Alnylam Pharmaceuticals 22.82% 58.64% ★★★★★★ Blueprint Medicines 22.38% 55.75% ★★★★★★ Applied Optoelectronics 58.93% 141.15% ★★★★★★ TKO Group Holdings 21.90% 25.17% ★★★★★★ Lumentum Holdings 21.55% 119.67% ★★★★★★

Click here to see the full list of 240 stocks from our US High Growth Tech and AI Stocks screener.

We're going to check out a few of the best picks from our screener tool.

Gyre Therapeutics

Simply Wall St Growth Rating: ★★★★★☆

Overview: Gyre Therapeutics, Inc. is a pharmaceutical company focused on developing and commercializing small-molecule drugs for treating organ fibrosis, with a market cap of $886.54 million.

Operations: Gyre Therapeutics generates revenue primarily through its Gyre Pharmaceuticals segment, which reported $105.03 million in revenues. The company focuses on developing and commercializing small-molecule drugs targeting organ fibrosis, emphasizing anti-inflammatory and anti-fibrotic treatments.

Gyre Therapeutics, amidst a dynamic biotech landscape, is making notable strides with an anticipated revenue growth of 42.6% annually, outpacing the U.S. market average of 8.4%. This growth projection aligns with recent strategic board changes aimed at enhancing governance and international expertise, potentially bolstering Gyre's position in global markets. Despite current unprofitability, the company is expected to pivot to profitability within three years, a trajectory that suggests robust operational improvements and market adaptation. Gyre’s focus on innovative therapeutic solutions continues to attract attention as evidenced by their active participation in industry conferences such as BIO Partnering @JPM Week.

Navigate through the intricacies of Gyre Therapeutics with our comprehensive health report here. Review our historical performance report to gain insights into Gyre Therapeutics''s past performance.NasdaqCM:GYRE Earnings and Revenue Growth as at Mar 2025

2seventy bio

Simply Wall St Growth Rating: ★★★★☆☆

Overview: 2seventy bio, Inc. is a cell and gene therapy company dedicated to researching, developing, and commercializing cancer treatments in the United States, with a market cap of $255.36 million.

Story Continues

Operations: Focused on cancer treatment, 2seventy bio generates revenue primarily from its biotechnology segment, totaling $45.62 million.

Amidst a transformative phase in biotech, 2seventy bio has captured attention with its upcoming acquisition by Bristol Myers Squibb for approximately $286 million, a testament to its strategic value and promising developments in CAR T-cell therapies. This deal, enhancing the trajectory of treatments like Abecma for multiple myeloma, underscores 2seventy's pivotal role despite recent unprofitability. With revenue growth at 10.9% annually and earnings projected to surge by 61.9%, the company is poised for significant advancements post-acquisition, bolstered by robust R&D investments that align with industry innovation trends.

Unlock comprehensive insights into our analysis of 2seventy bio stock in this health report. Evaluate 2seventy bio's historical performance by accessing our past performance report.NasdaqGS:TSVT Revenue and Expenses Breakdown as at Mar 2025

VTEX

Simply Wall St Growth Rating: ★★★★☆☆

Overview: VTEX offers a software-as-a-service digital commerce platform tailored for enterprise brands and retailers, with a market capitalization of $802.56 million.

Operations: The company generates revenue primarily from its internet software and services segment, amounting to $226.71 million.

VTEX, amidst a robust tech landscape, has demonstrated notable financial resilience and strategic foresight. Recently turning profitable, the company reported a substantial increase in net income to $12 million for the year ended December 2024, up from a loss of $13.69 million the previous year. This turnaround is underscored by an impressive annual earnings growth forecast of 39.1%. Additionally, VTEX's commitment to innovation is evident in its R&D investments which align with its revenue growth projections of 13.2% annually. The firm also actively returned value to shareholders by repurchasing over 3 million shares for $20.23 million recently, reflecting confidence in its operational trajectory and future prospects within the competitive Interactive Media and Services sector.

Get an in-depth perspective on VTEX's performance by reading our health report here. Explore historical data to track VTEX's performance over time in our Past section.NYSE:VTEX Revenue and Expenses Breakdown as at Mar 2025

Seize The Opportunity

Take a closer look at our US High Growth Tech and AI Stocks list of 240 companies by clicking here. Are any of these part of your asset mix? Tap into the analytical power of Simply Wall St's portfolio to get a 360-degree view on how they're shaping up. Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world.

Ready For A Different Approach?

Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NasdaqCM:GYRENasdaqGS:TSVT and NYSE:VTEX.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments